IGC Pharma, Inc. announced an Artificial Intelligence (AI) collaboration with Los Andes University?s Center for Research and Training in Artificial Intelligence (?CINFONIA?). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients. CINFONIA is the Center for Research and Training in Artificial Intelligence led by Professor Pablo Arbelaez at the University of Los Andes Department of Biomedical Engineering.

CINFONIA integrates academic excellence, ethical principles, and responsible research to fulfill its mission of transforming the world with Artificial Intelligence for the benefit of humanity. IGC Pharma and CINFONIA jointly intend to develop and train deep learning algorithms based on state-of-the- art transformer architectures to predict the temporal progression of approximately 1,500 physiological and psychological variables for each patient enrolled in the IGC-AD1 Phase 2 clinical trial. These variables encompass neuropsychiatric scales, blood pressure, diet, and more intricate elements such as genetic markers and over 100 other biomarkers.

The team has become implementing a deep learning algorithm to develop an adversary-based optimization methodology to enable the interpretation of non-linear relationships between these input variables and treatment outcomes, like efficacy and adverse events. The strategic integration of AI is an essential initiative for IGC Pharma as the Company is pursuing five assets developed to target Alzheimer's disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, which are in different stages of development.